You are here: Home News Topical Paromomycin + Gentamicin Cream is Available to Treat Cutaneous Leishmaniasis in Department of Defense Beneficiaries

Topical Paromomycin + Gentamicin Cream is Available to Treat Cutaneous Leishmaniasis in Department of Defense Beneficiaries

This expanded access treatment program now makes topical paromomycin + gentamicin cream available for the treatment of Department of Defense (DoD) healthcare beneficiaries with uncomplicated cutaneous leishmaniasis (CL).

The US Army Medical Materiel Development Activity (USAMMDA) has been conducting studies in several countries using paromomycin+gentamicin cream, with the largest of these studies to date completed in Tunisia in 2011 (Ben Salah, et.al., NEJM 368(6):524). USAMMDA has agreed to make this medication available to DoD healthcare beneficiaries. For additional information pleave visit Members section or contact Dr Naomi Aronson via USAMMDA at usarmy.detrick.medcom-usammda.list.leishmania-tx-protocol@mail.mil.